✦ LIBER ✦

808: The PI3K/mTOR inhibitor NVP-BEZ235 is able to revert selumetinib resistance in colorectal cancer cellular models

✍ Scribed by Martinez-Lacaci, I.; Carballo-Santana, M.; Tristante, E.; Mayor-López, L.; Grasso, S.; Carbonell, P.; De Torre, C.; Luján, J.; Alonso, J.L.; Carballo, F.

Book ID: 125796766
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 64 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(14)50713-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Dual PI3K/mTOR Inhibitor NVP-BEZ235

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model for Sporadic Colorectal Cancer

✍ Jatin Roper; Michael P. Richardson; Wei Vivian Wang; Larissa Georgeon Richard; W 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 198 KB

219 POSTER NVP-BEZ235, a dual pan-PI3K/m

219 POSTER NVP-BEZ235, a dual pan-PI3K/mTOR kinase inhibitor, is effective in human lung cancer models harboring EGFR mutations

✍ C.R. Schnell; J. Vaxelaire; M. Vogelsanger; M. Hattenberger; F. Stauffer; S. Arn 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

The efficacy of a novel, dual PI3K/mTOR

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI

369 Effects of the Specific PI3K Inhibit

369 Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib

✍ Serova, M.; Raballand, A.; Dos Santos, C.; Riveiro, E.; Raymond, E.; Faivre, S.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

823 COMBINED TREATMENT WITH CISPLATIN AN

823 COMBINED TREATMENT WITH CISPLATIN AND DUAL PI3K-MTOR INHIBITOR NVP-BEZ235 CAN RESTORE CASPASE DEPENDENT APOPTOSIS IN CISPLATIN RESISTANT HUMAN BLADDER CANCER CELL THROUGH THE DOWN-REGULATION OF C-FLIP

✍ S.S. Bvun; C.Y. Yoon; M.J. Park; S.W. Doo; H.Z. Park; D.S. Kim; W.K. Lee; S.H. P 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 133 KB

971 COMBINED TREATMENT WITH CISPLATIN AN

971 COMBINED TREATMENT WITH CISPLATIN AND DUAL PI3K-MTOR INHIBITOR NVP-BEZ235 CAN RESTORE CASPASE DEPENDENT APOPTOSIS IN CISPLATIN RESISTANT HUMAN BLADDER CANCER CELL THROUGH THE DOWN-REGULATION OF C-FLIP

✍ Yoon, Cheol Yong; Park, Mi Jung; Doo, Seung Whan; Park, Hong Zoo; Kim, Dae Sung; 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 118 KB